Halozyme Therapeutics.
Company
- Reports this week
- 1
- Active events
- 1
- Connections
- 52
What's happening
Active this week
One to three months ago
-
Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.Some support2 reports1 development inside
-
Halozyme tracks patient usage of OCREVUS ZUNOVO and monitors Opdivo Qvantig sales and conversion rates.Some support1 report
Gone quiet
No new reports in 90+ days-
Halo, a biopharmaceutical company based in San Diego, and Leidos and TransUnion are mentioned as stocks for investment.Some support14 reports
-
Halozyme Therapeutics, listed on Nasdaq, received a buy rating from TD Cowen, which was disclosed to the SEC.Some support2 reports
-
Halozyme Therapeutics received European regulatory approval, while Morgan Stanley upgraded its stock and it filed a patent lawsuit against Merck Sharp & Dohme.Well supported3 reports
-
CMS drug pricing guidance introduces uncertainty and regulatory changes affect royalty revenue growth for Halozyme Therapeutics.Some support2 reports
-
Halozyme Therapeutics' ENHANZE technology is being utilized by major pharmaceutical companies including AbbVie, Roche, and Lilly.Some support5 reports
-
Morgan Stanley raised price targets on Halozyme Therapeutics, noting the company may benefit from Trump-era tariffs.Some support4 reports
-
Janssen received EC approval for DARZALEX Faspro co-formulated with ENHANZE.Some support1 report
-
H.C. Wainwright analysts raised the price target for Halozyme Therapeutics on August 12, 2025.Some support1 report
-
T. Rowe Price and Halozyme Therapeutics were highlighted as strong investment opportunities on September 3, 2025.Some support1 report
-
Halozyme Therapeutics' stock gain contrasts with the performance of the medical sector.Some support5 reports
No events began in the chosen period. Widen it, or reset.
Around Halozyme Therapeutics this week
News at the entities that move Halozyme Therapeutics most-
AbbVie StructuralKori Wallace was appointed vice president at AbbVie.Moves Halozyme Therapeutics
-
Hoffmann-La Roche StructuralHoffmann-La Roche and Danaher are partnering with Nvidia to develop AI-driven labs for R&D and advance autonomous science.Moves Halozyme Therapeutics
-
Leerink partners Mentioned togetherLeerink Partners is acting as a placement agent for First Tracks Biotherapeutics.Moves Halozyme Therapeutics
-
SEC StructuralLedjr AI acquired voting control of SPYR, which must now file a registration statement with the SEC and aims for a Nasdaq listing.Moves Halozyme Therapeutics
-
Incyte OperationalIncyte is scheduled to present research data at the European Society for Medical Oncology (ESMO) congress in Madrid.Moves Halozyme Therapeutics
-
Morgan Stanley Mentioned togetherSEC filings disclosed executive stock purchases for Applied Digital Corp, and Morgan Stanley raised its price target.Moves Halozyme Therapeutics
Connections
The 20 strongest of 52, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AbbVie Structural
AbbVie utilizes proprietary ENHANZE technology licensed from Halozyme Therapeutics.
-
Hoffmann-La Roche Structural
Roche utilizes Halozyme's ENHANZE drug delivery technology under a licensing agreement, generating royalty payments.
-
Bristol-Myers Squibb Structural
Halozyme licensed its ENHANZE drug delivery technology to Bristol-Myers Squibb, establishing a technology supply dependency.
-
Incyte Operational
The companies have established a global partnership to develop subcutaneous formulations of the drug candidate INCA033989.
-
Merck Operational
Halozyme and Merck are engaged in ongoing intellectual property litigation over MDASE patents.
-
Pfizer Transactional
Halozyme repeatedly licensed its ENHANZE technology to Pfizer.
-
Janssen Structural
Halozyme licenses its ENHANZE technology to Janssen, which uses it to co-formulate pharmaceutical products.
-
Nasdaq Structural
Halozyme Therapeutics is a publicly listed company on the Nasdaq exchange.
Show all 20 connections
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial analysis, including price targets and upgrades, on Halozyme Therapeutics.
-
Vertex Pharmaceuticals Structural
The relationship is characterized by a formal partnership structure where one entity operates as a subsidiary regarding Hypercon technology.
-
Leerink partners Mentioned together
Leerink Partners functions as an analyst firm, providing market research reports and assessments on Halozyme Therapeutics.
-
SEC Structural
Halozyme Therapeutics is subject to formal oversight and disclosure requirements of the SEC.
-
Benchmark Mentioned together
Benchmark provides analyst coverage, including Buy ratings and stock monitoring, for Halozyme Therapeutics.
-
TD Cowen Transactional
TD Cowen provided and reaffirmed a buy rating on Halozyme Therapeutics shares.
-
NeoGenomics Mentioned together
Both NeoGenomics and Halozyme Therapeutics are listed as top holdings in a First Trust fund.
-
Corcept Therapeutics Mentioned together
Both companies are included in the same First Trust investment fund.
-
Belgium Shared context
Halozyme Therapeutics operates within the geographical context of Belgium.
-
San Diego Shared context
Halozyme Therapeutics is headquartered and based in San Diego, California.
-
Biotech Mentioned together
Halozyme Therapeutics is classified as a biopharma technology platform company, placing it within the broader biotech sector.
-
Citigroup Mentioned together
No evidence was found in the timeline linking Citigroup and Halozyme Therapeutics.
History
Events by the month they beganOctober 2026
1 eventAugust 2026
1 eventJune 2026
11 events- Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.
- Halo, a biopharmaceutical company based in San Diego, and Leidos and TransUnion are mentioned as stocks for investment.
- Halozyme Therapeutics, listed on Nasdaq, received a buy rating from TD Cowen, which was disclosed to the SEC.
- Halozyme Therapeutics received European regulatory approval, while Morgan Stanley upgraded its stock and it filed a patent lawsuit against Merck Sharp & Dohme.
- CMS drug pricing guidance introduces uncertainty and regulatory changes affect royalty revenue growth for Halozyme Therapeutics.
- Halozyme Therapeutics' ENHANZE technology is being utilized by major pharmaceutical companies including AbbVie, Roche, and Lilly.
- Morgan Stanley raised price targets on Halozyme Therapeutics, noting the company may benefit from Trump-era tariffs.
- Janssen received EC approval for DARZALEX Faspro co-formulated with ENHANZE.
- H.C. Wainwright analysts raised the price target for Halozyme Therapeutics on August 12, 2025.
- T. Rowe Price and Halozyme Therapeutics were highlighted as strong investment opportunities on September 3, 2025.
- Halozyme Therapeutics' stock gain contrasts with the performance of the medical sector.